Maze Therapeutics Inc

{ "date": [ "202612", "202712", "202812", "202912", "203012" ], "revenue_estimate": [ 22, 8.85, 8.29, 38.23, 242.32 ], "ebit_estimate": [ -171.04, -213.7, -265.46, -296.32, -183.97 ], "ebitda_estimate": [ -183, -222, -237, null, null ], "net_income_estimate": [ -160.51, -205.8, -257.54, -288.24, -175.11 ], "per_share_eps_estimate": [ -2.8, -3.3, -3.74, -3.96, -2.39 ], "eps_nri_estimate": [ -2.8, -3.3, -3.74, -3.96, -2.39 ], "dividend_estimate": [ null, null, null, null, null ], "book_value_per_share_estimate": [ 6.22, 6.33, 3.65, null, null ], "pretax_income_estimate": [ -157.36, -204.81, -260.88, -305.03, -191.63 ], "operating_cash_flow_per_share_estimate": [ -2.37, -2.55, -2.67, null, null ], "roa_estimate": [ -40.8, -43.5, -51.4, null, null ], "roe_estimate": [ -48, -53, -65.4, null, null ], "gross_margin_estimate": [ 100, null, null, 137.5, 91.67 ], "operating_cash_flow_estimate": [ -127.74, -137.44, -143.91, null, null ], "pettm_estimate": [ 0, 0, 0, 0, 0 ], "long_term_growth_rate_mean": -8.04, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -8.04, "future_eps_nri_estimate_growth": -8.04, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -23.13, "future_ebitda_estimate_growth": -19.27, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -25.53, "future_pretax_income_estimate_growth": -26.21, "future_book_value_per_share_estimate_growth": -18.28, "future_roa_estimate_growth": -7.63, "future_roe_estimate_growth": 48.03, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }

{ "date": [ "202606", "202609", "202612", "202703", "202706", "202709", "202712" ], "revenue_estimate": [ 2, null, null, 3, 3, 3, 3 ], "ebit_estimate": [ -45.24, -48.67, -50.51, -50.68, -51.92, -52.38, -55.4 ], "ebitda_estimate": [ -48, -52, -56, null, null, null, null ], "net_income_estimate": [ -42.42, -46.26, -47.95, -48.64, -50.22, -50.86, -54.06 ], "per_share_eps_estimate": [ -0.73, -0.79, -0.81, -0.84, -0.83, -0.83, -0.87 ], "eps_nri_estimate": [ -0.73, -0.79, -0.81, -0.84, -0.83, -0.83, -0.87 ], "dividend_estimate": [ null, null, null, null, null, null, null ], "book_value_per_share_estimate": [ null, null, null, null, null, null, null ], "pretax_income_estimate": [ -40.91, -45.19, -47.11, -48.68, -50.25, -50.65, -54.18 ], "operating_cash_flow_per_share_estimate": [ null, null, null, null, null, null, null ], "roa_estimate": [ null, null, null, null, null, null, null ], "roe_estimate": [ null, null, null, null, null, null, null ], "gross_margin_estimate": [ null, null, null, null, null, null, null ], "operating_cash_flow_estimate": [ null, null, null, null, null, null, null ], "pettm_estimate": [ 0, 0, 0, 0, null, null, null ], "long_term_growth_rate_mean": -8.04, "long_term_revenue_growth_rate_mean": "0.00", "future_per_share_eps_estimate_growth": -8.04, "future_eps_nri_estimate_growth": -8.04, "future_revenue_estimate_growth": null, "future_ebit_estimate_growth": -23.13, "future_ebitda_estimate_growth": -19.27, "future_dividend_estimate_growth": null, "future_net_income_estimate_growth": -25.53, "future_pretax_income_estimate_growth": -26.21, "future_book_value_per_share_estimate_growth": -18.28, "future_roa_estimate_growth": -7.63, "future_roe_estimate_growth": 48.03, "future_gross_margin_estimate_growth": null, "future_operating_cash_flow_per_share_estimate_growth": null }